Publications
Talk to Our Care TeamReal World Data of the safety and efficacy of Talicabtagene Autoleucel (Humanized CD19 CAR-T) in relapsed / refractory B-cell acute lymphoblastic leukemia from India.
Poster
Jun 12, 2025European Hematology Association Congress
Safety And Efficacy Of Polatuzumab Vedotln Plus Glontamab As Bridging Therapy Prior To Talicabtagene Autoleucel For Relapsed/Refractory B-cell Lymphoma
Poster
Jun 12, 2025European Hematology Association Congress
Bridging The Gap: Inotuzumab Integration Prior To Talicabtagene Autoleucel In R/R B-ALL
Poster
Jun 12, 2025European Hematology Association Congress
Development of equitable access model for nationwide implementation of affordable CAR-T cell therapy in India a real-world experience
Poster
May 10, 2025International Society for Cell and Gene Therapy
Development of equitable access model for nationwide implementation of affordable CAR-T cell therapy in India: a real-world experience.
Article
May 10, 2025Cytotherapy
Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel™) cells in relapsed/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I/Ib study
Article
Apr 24, 2025Blood Cancer Journal
Talicabtagene Autoleucel for Relapsed or Refractory B-cell Malignancies: Results from an Open-label, Multicentre, Phase 1/2 Study
Article
Apr 1, 2025The Lancent Haematology
Real world data of novel Talicabtagene autoleucel (humanized CD19 CAR-T) from India; ensuring equitable access with excellent safety and efficacy profile
Poster
Dec 7, 2024American Society of Hematology Meeting
Real world data of novel Talicabtagene autoleucel (humanized CD19 CAR-T) from India; ensuring equitable access with excellent safety and efficacy profile
Abstract
Nov 5, 2024American Society of Hematology Meeting
Development of a Novel Humanized BCMA-Directed CAR for Multiple Myeloma: Robust Activity and Low Toxicity in Preclinical Studies
Poster
Dec 7, 2024American Society of Hematology Meeting
Development of a Novel Humanized BCMA-Directed CAR for Multiple Myeloma: Robust Activity and Low Toxicity in Preclinical Studies
Abstract
Nov 5, 2024American Society of Hematology Meeting
High Efficacy and Excellent Safety Profile of Actalycabtagene Autoleucel, a Humanized CD19 CAR-T Product in r/r B-Cell Malignancies: A Phase II Pivotal Trial
Poster
Dec 9, 2023American Society of Hematology Meeting
High Efficacy and Excellent Safety Profile of Actalycabtagene Autoleucel, a Humanized CD19 CAR-T Product in r/r B-Cell Malignancies: A Phase II Pivotal Trial
Abstract
Nov 2, 2023American Society of Hematology Meeting
Excellent Safety Profile of a Low-Cost Novel Humanized CD19 CAR T-Cell Therapy, Actalycabtagene Autoleucel : Potential Impact on Access and Feasibility
Poster
Dec 9, 2023American Society of Hematology Meeting
Excellent Safety Profile of a Low-Cost Novel Humanized CD19 CAR T-Cell Therapy, Actalycabtagene Autoleucel : Potential Impact on Access and Feasibility
Abstract
Nov 2, 2023American Society of Hematology Meeting
Making Anti-CD19 CAR-T Cell Therapy Accessible and Affordable: First-in-Human Phase I Clinical Trial Experience from India
Poster
Dec 10, 2022American Society of Hematology Meeting
Making Anti-CD19 CAR-T Cell Therapy Accessible and Affordable: First-in-Human Phase I Clinical Trial Experience from India
Abstract
Nov 15, 2022American Society of Hematology Meeting
Robust Antitumor Activity and Low Cytokine Production by Novel Humanized Anti-CD19 CAR T Cells
Article
May 1, 2021Moecular Cancer Therapeutics